Shire says it is closing in December a plasma fractionating facility in Los Angeles, California, but remains positive it can successfully manage its post-Baxalta manufacturing network of 17 sites, according to an article in BioPharma-Reporter.
Shire's CEO Flemming Ornskov made the announcement during a conference call revealing its Q3 results and said the move was the first part of a "network strategy [which] will be laid out next year."
Read the full story
